The "2015 Asia Pacific Biotech Investment Forum", jointly organized by the leading venture fund, Diamond Biofund, and Institute for Biotechnology and Medicine Industry, with the title " Innovation Join Hands with Venture Capital, Focus on the Asian Business Strategy" was launched on July 21 followed by a series of Taiwan's biotechnology activities.

Not only the Wei-Cho Chen, Ph.D., Chairman of Institute for Biotechnology and Medicine Industry, Tyzz Jiun Duh, Executive Yuan, Minister gave a welcome speech, Xiangyu Ouyang, Managing Director of Legend Capital, Jiang Zhang, Director of Ping An Ventures, and Sam Thong, Senior Advisor of Morgan Stanley Asia Limited were also shared cross - strait biotechnology investment trends.

Wei-Cho Chen, Ph.D., Chairman of Institute for Biotechnology and Medicine Industry (IBMI), pointed out because of government cultivate Taiwan's biotechnology industry through the legislation that the environment is getting mature. In additional, there were many potential and competitive high-end technologies of Taiwan research institutions can continually inject innovative energy for the industry. Together with Diamond Biofund, IBMI found three potential technologies last year, and Diamond Biofund invested about 1.8 billion to assist them to set up company, which is the great model of collaboration between academia and industry.

"Asia Pacific Biotech Investment Forum is to let international funds see Taiwan." William Lu, Chairman of Diamond Biofund said, Diamond Biofund also hope to join hands to form a four major venture capital strategic alliance to scale more than NTD 35 billion of biotechnology investment funds into the cross-strait health industry development. The organizer Diamond Biofund, since the establishment of more than 1 year, the fund scaled up from NTD 4 billion to 8 billion, has become the largest domestic biotechnology fund, and planned to retain NTD 2 billion for international financial cooperation, expanded to 10 billion. Last year a total investment was NTD 1.8 billion; this year the accounting profit was NTD 1.6 billion.

In this forum, the Diamond Biofund also signed strategic cooperation agreements with some attended companies to jointly promote cross-regional Asia-Pacific biotech investment.